Gossamer Bio appoints Dr. Nathan (PH-ILD expert) and biotech analyst Drynan to board

Gossamer Bio, Inc.

Dr. Steven Nathan appointed as Class I director, effective March 11, 2024; brings pulmonary and PH-ILD expertise.
Skye Drynan appointed as Class III director; former Capital Group Partner and Senior BioPharma Analyst.
Each new director receives $40,000 annual cash retainer and option for 230,000 shares vesting over three years.
Dr. Nathan's guidance intended to support expansion of seralutinib clinical program into PH-ILD.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steven Nathan

Class I director

GOSS · Gossamer Bio, Inc.

Effective: 2024-03-11
Filed: March 12, 2024, 7:59 PM ET

Steven Nathan, M.D. to serve as a Class I director effective March 11, 2024

Appointed

Skye Drynan

Class III director

GOSS · Gossamer Bio, Inc.

Effective: 2024-03-11
Filed: March 12, 2024, 7:59 PM ET

appointed Skye Drynan to serve as a Class III director effective March 11, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Nathan was appointed as Class I director at Gossamer Bio, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

Steven Nathan, M.D. to serve as a Class I director effective March 11, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Skye Drynan was appointed as Class III director at Gossamer Bio, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

appointed Skye Drynan to serve as a Class III director effective March 11, 2024

View on SEC.gov

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-24-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.